Aegion (AEGN) Forms $22.53 Double Bottom; Blue Martini Software (BLUE)’s Sentiment Is 1.68

October 13, 2017 - By Richard Conner

Aegion Corp (AEGN) formed double bottom with $20.95 target or 7.00% below today’s $22.53 share price. Aegion Corp (AEGN) has $743.76 million valuation. The stock increased 0.31% or $0.07 during the last trading session, reaching $22.53. About shares traded. Aegion Corp (NASDAQ:AEGN) has risen 2.91% since October 13, 2016 and is uptrending. It has underperformed by 13.79% the S&P500.

bluebird bio, Inc. is a clinical-stage biotechnology company. The company has market cap of $5.94 billion. The Firm is focused on developing gene therapies for severe diseases and cancer. It currently has negative earnings. With its lentiviral gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas.

Among 5 analysts covering Aegion (NASDAQ:AEGN), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Aegion had 16 analyst reports since January 5, 2016 according to SRatingsIntel. The stock of Aegion Corp (NASDAQ:AEGN) earned “Buy” rating by Canaccord Genuity on Thursday, August 3. Hilliard Lyons upgraded Aegion Corp (NASDAQ:AEGN) on Wednesday, October 4 to “Buy” rating. Sidoti upgraded Aegion Corp (NASDAQ:AEGN) on Tuesday, November 22 to “Buy” rating. The stock of Aegion Corp (NASDAQ:AEGN) earned “Buy” rating by Craig Hallum on Tuesday, May 23. Stifel Nicolaus maintained the shares of AEGN in report on Thursday, July 6 with “Hold” rating. The stock of Aegion Corp (NASDAQ:AEGN) has “Buy” rating given on Thursday, August 10 by Canaccord Genuity. The company was downgraded on Tuesday, October 3 by Craig Hallum. The firm has “Neutral” rating by Sidoti given on Friday, March 11. The stock of Aegion Corp (NASDAQ:AEGN) has “Neutral” rating given on Monday, June 27 by Sidoti. The firm earned “Hold” rating on Tuesday, October 3 by Stifel Nicolaus.

Analysts await Aegion Corp (NASDAQ:AEGN) to report earnings on October, 30. They expect $0.42 EPS, up 31.25% or $0.10 from last year’s $0.32 per share. AEGN’s profit will be $13.87M for 13.41 P/E if the $0.42 EPS becomes a reality. After $0.34 actual EPS reported by Aegion Corp for the previous quarter, Wall Street now forecasts 23.53% EPS growth.

Investors sentiment decreased to 0.99 in 2017 Q2. Its down 0.28, from 1.27 in 2017Q1. It dropped, as 16 investors sold Aegion Corp shares while 51 reduced holdings. 22 funds opened positions while 44 raised stakes. 29.24 million shares or 0.00% less from 29.25 million shares in 2017Q1 were reported. Savings Bank Of Ny Mellon invested in 412,590 shares or 0% of the stock. Prudential invested in 320,176 shares or 0.01% of the stock. 100 were accumulated by Winslow Evans Crocker. Aqr Capital Ltd Liability Company stated it has 33,968 shares. Jefferies Group holds 0% or 9,600 shares. Barclays Public Ltd reported 0% stake. Metropolitan Life Ins New York stated it has 25,368 shares or 0% of all its holdings. Deutsche Bancorporation Ag holds 459,695 shares or 0.01% of its portfolio. Mason Street Advsrs Ltd Liability has 0% invested in Aegion Corp (NASDAQ:AEGN) for 8,259 shares. Pinebridge Investments Lp reported 0.03% stake. Us Comml Bank De holds 0% of its portfolio in Aegion Corp (NASDAQ:AEGN) for 2,302 shares. Envestnet Asset Mgmt, a Illinois-based fund reported 343 shares. Snow L P stated it has 74,000 shares. Nuveen Asset Management Limited Liability accumulated 365,583 shares. Howe Rusling Inc has invested 0.09% in Aegion Corp (NASDAQ:AEGN).

Ratings analysis reveals 50% of Bluebirdbio’s analysts are positive. Out of 4 Wall Street analysts rating Bluebirdbio, 2 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. The lowest target is $80.0 while the high is $87.0. The stock’s average target of $83.50 is -35.87% below today’s ($130.2) share price. BLUE was included in 4 notes of analysts from October 14, 2016. The stock of bluebird bio Inc (NASDAQ:BLUE) earned “Sell” rating by Cantor Fitzgerald on Friday, October 14. Maxim Group maintained the stock with “Buy” rating in Thursday, December 1 report. The firm has “Outperform” rating by Leerink Swann given on Friday, October 14. The firm earned “Neutral” rating on Monday, February 6 by Roth Capital.

The stock increased 3.79% or $4.75 during the last trading session, reaching $130.2. About shares traded. bluebird bio Inc (BLUE) has risen 112.34% since October 13, 2016 and is uptrending. It has outperformed by 95.64% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com